A 22-Point Matrisome Profiling Standard Exposes the Gap between Marketing Claims and Biological Evidence in Aesthetic Medicine

The Great Skin Reboot: A Reality Check

Imagine your skin isn't just a covering, but a bustling, high-tech city. This city is built on a complex framework called the extracellular matrix. Think of this matrix as the city's infrastructure: it has the steel beams (collagen) that hold everything up, the rubber bands (elastin) that let the city bounce back after a storm, and a sophisticated power grid (homeostasis) that keeps the lights on and the traffic flowing. When we talk about "regeneration" in science, we aren't just talking about patching a pothole; we mean rebuilding the entire city so it looks, feels, and functions exactly like a brand-new metropolis.

For years, the world of aesthetic medicine (the field dedicated to making us look younger) has been shouting that its treatments are "regenerative." They claim to reboot the skin's city, turning back the clock and restoring the original blueprint. But here's the problem: while the marketing slogans are loud and bright, the actual blueprints and construction reports have been missing. Scientists have been using a very loose definition of "regeneration," often pointing to a single pile of bricks (collagen) and calling it a finished skyscraper. This paper asks a simple, tough question: If we demand a full, rigorous inspection of the construction site, do these treatments actually rebuild the city, or are they just putting up a fresh coat of paint?

The 22-Point Inspection

To answer this, the authors created a strict new rulebook called the Matrisome Profiling Standard (MPS). Imagine a massive, 22-point checklist that a building inspector would use to declare a city "fully regenerated." This checklist doesn't just look for bricks; it checks seven different neighborhoods of the skin city:

1. Gene Expression: Are the blueprints being rewritten correctly?
2. Protein Synthesis: Are the workers actually building the materials?
3. Structural Assembly: Is the steel arranged in the right pattern?
4. Functional Biomechanics: Does the building bounce back when you push it?
5. Homeostatic Regulation: Is the power grid stable?
6. Cellular Rejuvenation: Are the old workers replaced by young, energetic ones?
7. Epigenetic Reactivation: Is the "aging switch" turned off?

The researchers took this 22-point checklist and applied it to 136 published studies on popular aesthetic treatments, including injectable fillers, lasers, and "biostimulators" (products designed to wake up the skin's own repair crew). They looked at everything from the year 2001 up to June 2026.

The Shocking Scorecard

The results were a bit of a reality check. Out of a perfect score of 22, no single study managed to score higher than 5.0.

To put that in perspective, the highest score of 5.0 was achieved by a study done in a test tube (in vitro), not on a real human. The highest score for a real human (in vivo) was just 4.0. When the researchers looked at the "fully reconciled" primary studies—the core evidence—they found that 76.5% of them provided "inadequate evidence," scoring between 0 and 0.5.

The authors classify these scores into categories:

• True Regeneration: 22 points (None found).
• Near-Regeneration: 18–21.5 points (None found).
• Substantial: 12–17.5 points (None found).
• Modest: 6–11.5 points (None found).
• Palliation: 1–5.5 points (This is where almost everything landed).
• Inadequate: 0–0.5 points (The majority of studies).

"Palliation" is a fancy word for "making things feel better temporarily without fixing the root cause." It's like putting a bandage on a leaky pipe instead of replacing the pipe. The paper concludes that current aesthetic interventions are mostly palliative, not regenerative.

What Was Missing?

The inspection revealed a massive gap in what scientists were actually measuring. Almost every study focused on just one thing: Collagen Type I and III. It's as if every city inspector only counted the number of bricks and ignored the steel beams, the rubber bands, the electricity, and the plumbing.

• Collagen: 71.3% of studies looked at this.
• Elastin (the rubber bands): Only 9.6% looked at this.
• Structural Assembly (how the bricks are stacked): Only 2.9% checked this.
• Biomechanics (does it bounce?): Only 7.4% checked this.
• Epigenetic Reactivation (the aging switch): A tiny 1.5% of studies even touched on this.

Even the popular "biostimulators" like Poly-L-lactic acid (PLLA) and Calcium Hydroxylapatite (CaHA), which are marketed heavily as regeneration tools, scored very low. PLLA studies ranged from 0 to 3.0, and CaHA studies ranged from 0 to 1.5. None of them checked for the complex structural or genetic changes required to prove true regeneration.

The "Low Risk" Problem

The paper also looked at how these studies were conducted and found that the quality of the evidence was shaky. When they checked for bias (like whether the researchers knew which treatment was which, or if they only reported the good results), none of the studies achieved a "Low risk of bias."

• 90.5% of studies lacked blinding (the inspectors knew what they were looking at).
• 71.4% lacked a control group (no comparison to a "do nothing" group).
• 83.3% had very small sample sizes.

This suggests that the field has been operating in an "evidentiary vacuum," where big claims are made without the rigorous data to back them up.

The Bottom Line

The authors aren't saying these treatments don't work at all. They admit that fillers add volume and lasers improve texture. However, they argue that calling these effects "regeneration" is misleading because the evidence doesn't support the claim that the skin's entire biological city has been rebuilt.

The paper suggests that until a study can score high on all 22 points of the MPS—proving that the genes, proteins, structure, and function are all restored—we should stop using the word "regeneration" as a marketing buzzword. Instead, we should be honest that these treatments offer "palliation" (temporary improvement) rather than a true biological reboot. The goal, according to the authors, is to give patients a clear, standardized language so they know exactly what they are buying: a temporary fix, or a scientifically proven rebuild. Until then, the gap between the marketing claims and the biological reality remains wide open.